CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
onabotulinumtoxinA +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02230956
NCT02230956Phase 2Completed

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

Allergan·interventional·Posted Sep 3, 2014·Updated May 31, 2017

In Brief

A Phase 2 clinical trial evaluating onabotulinumtoxinA and Normal Saline for Osteoarthritis. Completed, enrolled 176 participants across 3 sites in 3 countries.

Detailed Summary

This study will evaluate the efficacy and safety of a single intra-articular injection of 2 doses of BOTOX® (onabotulinumtoxinA) compared with placebo as treatment for knee osteoarthritis symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesCzechia, Denmark, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 3, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.8 years ago

Interventions

onabotulinumtoxinAbiological

onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.

Normal Salinedrug

Normal Saline (placebo) injection into the intra-articular space of the study knee.